Ludovic Helfgott, Novo Nordisk EVP and head of rare disease
Novo Nordisk execs had only one drug on their mind when they came calling at Forma. Here's the inside story of their $1.1B buyout
Novo Nordisk never hesitated in its pursuit of Forma’s sickle cell drug etavopivat. Dating back to the early part of 2021, Novo execs were reaching …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
